重组甘精胰岛素治疗2型糖尿病的有效性与安全性分析

Efficacy and safety analysis of Recombinant insulin glargine in treatment of Type 2 diabetes mellitus

目的探讨重组甘精胰岛素治疗2型糖尿病的有效性与安全性。方法选择本院治疗的2型糖尿病患者110例,随机分为治疗组和对照组各55例。所有患者均于入院内给予糖尿病相关知识的讲解,并于每日早餐前口服5mg格列吡嗪缓释片治疗。在此基础上,治疗组患者给予重组甘精胰岛素皮下注射治疗,对照组患者每日睡前皮下注射NPH1次。比较两组患者的血糖以及不良反应情况。结果两组患者治疗后餐前血糖、餐后2h血糖以及凌晨3:00血糖均较治疗前有明显的改善(P<0.05),而治疗后治疗组患者的餐前血糖、餐后2h血糖以及凌晨3:00血糖均明显优于对照组患者(P<0.05)。治疗组患者的血糖达标天数明显短于对照组患者(P<0.05),低血糖发生次数明显少于对照组患者(P<0.05)。两组患者治疗12周后,血、尿常规,肝肾功能检查、血脂检查以及心电图检查均无明显变化。结论重组甘精胰岛素治疗2型糖尿病具有疗效确切,不良反应少的特点,值得临床推广使用。

Objective To investigate efficacy and safety of recombinant insulin glargine in treatment of type 2 diabetes mellitus.Method One hundred and ten patients with type 2 diabetes mellitus treated in our hospital were randomly divid ed into two groups,treatment group and control group,55 cases in each group.Diabetes related knowledge were taught to all patients and 5 mg glipizide sustained release tablets were eaten before breakfast.On this basis,the treatment group were all given subcutaneous injections of recombinant insulin glargine and control group were given subcutaneous injec tions of NPH in daily bedtime.The blood glucose and adverse reactions were compared between two groups.Results After treatment,the blood glucose before meals,two hours after meals and 3：00 in the morning of two groups were all significantly better than before（P 0.05）;the blood glucose before meals,two hours after meals and 3：00 in the morning of treatment groups were significantly better than control group（P 0.05）.The days to reach the objective blood glucose of treatment group were shorter than control groups（P 0.05）.The occurrence of hypoglycemia in treatment group are lower than in control group（P 0.05）.There were no significantly differences between two groups on blood and urine routine tests,liver and kidney function tests,serum lipid checked and ECG examinations.Conclusion Recombinant insulin glargine in treatment of type 2 diabetes has a good efficacy and fewer adverse reactions.It is worthy of clinical application.